Shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) surged nearly 99% in premarket trading on Tuesday, reaching $83.60, just $1.40—or 1.7%—below Vertex Pharmaceuticals' (NASDAQ:VRTX) all-cash offer of $85 per share. The stock had closed Monday at $42.03, reflecting the dramatic shift from a biotech growth story to a merger-arbitrage play.
The deal, valued at approximately $10 billion in equity, or $8.8 billion net of Crinetics' estimated $1.2 billion cash, is set to close in the third quarter of 2026. Vertex has secured a $4.5 billion unsecured bridge loan backstop from Bank of America, BofA Securities, and Morgan Stanley Senior Funding, eliminating financing risk. The acquisition does not depend on external financing, according to the SEC filing.
The tight spread between the current trading price and the offer price suggests the market is pricing in a high probability of deal completion. With a gross spread of $1.40 per share, the annualized return for investors could range from 7.4% if the deal closes by September 30, 2026, to 3.4% if it extends to the outside date of January 6, 2027, and further down to 2.2% if a three-month extension option is exercised to April 6, 2027.
The break fee structure provides a safety net for investors. If the deal falls through under certain conditions, Crinetics would owe Vertex $350.5 million—equivalent to about $2.98 per share based on the fully diluted share count of approximately 117.6 million shares. This is well above the current $1.40 spread, indicating that the market sees minimal risk of deal failure.
Trading volume on Monday reached 5.42 million shares, representing 420% of the 65-day average, as the deal reset the stock's valuation. The merger still requires Crinetics shareholder approval, the expiration or termination of the Hart-Scott-Rodino waiting period, certain foreign clearances, and no legal obstacles.
Vertex is acquiring Crinetics primarily for its drug Palsonify (paltusotine), approved in the U.S. for adults with acromegaly, and atumelnant, a Phase 3 candidate for congenital adrenal hyperplasia. Vertex CEO Reshma Kewalramani stated that the deal brings endocrinology as a fifth therapeutic vertical and does not alter Vertex's R&D or capital allocation plans. Crinetics CEO Scott Struthers highlighted that Vertex's global infrastructure will accelerate the reach of Crinetics' science.
The combined peak annual sales of Palsonify and atumelnant are expected to exceed $5 billion, making the net purchase price of $8.8 billion less than 1.8 times that estimate. Scotiabank analyst Louise Chen noted that the deal strategically expands Vertex's pipeline into endocrinology.
Biotech sector benchmarks showed mixed reactions, with the iShares Nasdaq Biotechnology ETF (IBB) slipping 0.25% and the SPDR S&P Biotech ETF (XBI) edging up 0.16%. Crinetics' sharp move diverged from the broader sector's sideways performance.
